Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1Phase 3 1

Status

Unknown 9Recruiting 9Completed 8Withdrawn 3Not yet recruiting 2Terminated 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 2Breast 1

Conditions

Breast Neoplasms 111Carcinoma, Non-Small-Cell Lung 102Prostatic Neoplasms 66Multiple Myeloma 64Neoplasm Metastasis 63Colorectal Neoplasms 63Neoplasms 59Lung Neoplasms 51Leukemia, Myeloid, Acute 41Carcinoma, Hepatocellular 41Recurrence 40Lymphoma 40Leukemia, Lymphocytic, Chronic, B-Cell 36Pancreatic Neoplasms 34Melanoma 34Head and Neck Neoplasms 26Glioblastoma 26Rectal Neoplasms 25Ovarian Neoplasms 25Lymphoma, Large B-Cell, Diffuse 25Leukemia 24Brain Neoplasms 24Squamous Cell Carcinoma of Head and Neck 23Hematologic Neoplasms 23Carcinoma, Renal Cell 23Precursor Cell Lymphoblastic Leukemia-Lymphoma 22Myelodysplastic Syndromes 20Colonic Neoplasms 20Triple Negative Breast Neoplasms 19Lymphoma, Non-Hodgkin 19

Interventions

cc-486 1Sulindac 1Cytarabine 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Withdrawn × Pathologic Complete Response × Clear all
NCT06180863 2023-12-26

Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients

Yale University

Phase 2 Withdrawn
Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT05371860 2023-09-22

Radiation Omission in Patients With HER2 Overexpressing Tumors With Pathologic Complete Response

Cedars-Sinai Medical Center

Phase 2 Withdrawn
Breast

Pathologic Complete Response, Breast Neoplasms

NCT01843179 2017-02-17

Sulindac for Patients With AML

Massachusetts General Hospital

Phase 2 Withdrawn
Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡